[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345898-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345898-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mechanistic-evaluation-of-nsc-57774-as-a-shp2-inhibitor-in-gastric-cancer-multi-pathway-signaling-modulation-in-vitro","Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer - Multi-pathway signaling modulation in vitro","","Gastric cancer remains a leading cause of cancer mortality, with late diagnosis, metastasis, and resistance limiting effective therapy. Src homology region 2 domain-containing phosphatase 2 (SHP2) regulates oncogenic signaling in gastric tumors, yet therapeutic targeting is insufficiently explored. This study evaluates NSC 57774, a novel SHP2 inhibitor, combining bioinformatics and functional assays in gastric cancer cells to assess anti-cancer efficacy and multi-pathway signaling disruption in vitro.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mechanistic-evaluation-of-nsc-57774-as-a-shp2-inhibitor-in-gastric-cancer-multi-pathway-signaling-modulation-in-vitro/345898/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mechanistic-evaluation-of-nsc-57774-as-a-shp2-inhibitor-in-gastric-cancer-multi-pathway-signaling-modulation-in-vitro/345898.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is NSC 57774 and what does this study evaluate?","Question",{"text":63,"@type":64},"NSC 57774 is a novel SHP2 inhibitor. The study evaluates its anti-cancer efficacy and mechanistic impact on signaling pathways in gastric cancer cells in vitro.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the authors investigate SHP2 involvement in gastric cancer?",{"text":68,"@type":64},"They used integrated bioinformatics, analyzing TCGA and UALCAN datasets to identify upregulation of SHP2 and multiple receptor tyrosine kinases in gastric cancer tissues.",{"name":70,"@type":61,"acceptedAnswer":71},"Which signaling pathways are reported to be disrupted by NSC 57774?",{"text":72,"@type":64},"NSC 57774 disrupted key oncogenic pathways including MAPK/ERK, AKT, and STAT3, and it suppressed NF-κB inflammatory signaling at early timepoints.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345898,1790179576,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","OPEN ACCESS  \nCitation: Khoder G, Ghemrawi R, Sammani N, Harati R, Hamad M, Muhammad JS, et al.(2026) Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multipathway signaling modulation in vitro. PLoSOne 21(7): e0354605. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0354605](journal.pone.0354605)  \nEditor: Yung-Hsiang Chen, China Medical University, TAIWAN  \nReceived: January 21, 2026  \nAccepted: July 8, 2026  \nPublished: July 30, 2026  \nCopyright: © 2026 Khoder et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the manuscript and its Supporting  Information files.  \nFunding: University of Sharjah, Competitive Research Project No.(24011102102) and Targeted Research Project No. (25011102121) .  \nRESEARCH ARTICLE  \nMechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro  \nGhalia Khoder1,2☯*, Rose Ghemrawi3,4☯*, Nour Sammani3,4, Rania Harati2,5, Mohamad Hamad2,6, Jibran Sualeh Muhammad7, Walaa Mousa3,4, Mostafa Khair8  \n1 Department of Pharmaceutics and Pharmaceuticals Technology, College of Pharmacy, University of Sharjah, United Arab Emirates, 2 Research Institute for Medical & Health Sciences, University of Sharjah, United Arab Emirates, 3 College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates,  \n4 AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates, 5 Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates, 6 Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, United Arab Emirates, 7 Department of Biomedical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, 8 Core Technology Platforms, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates  \n☯ These authors contributed equally to this work.  \n* [gkhoder@sharjah.ac.ae](gkhoder@sharjah.ac.ae) (GK); [rose.ghemrawi@aau.ac.ae](rose.ghemrawi@aau.ac.ae) (RG)  \nAbstract  \nGastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, driven by late-stage diagnosis, metastatic progression, and therapeutic resistance. Src homology region 2 domain-containing phosphatase 2 (SHP2) has emerged as a critical regulator of oncogenic signaling in gastric tumorigenesis, yet its therapeutic targeting remains underexplored. In this study, we evaluated the anti-cancer efficacy of NSC 57774, a novel SHP2 inhibitor, using integrated bioinformatics and functional assays inAGS gastric cancer cells. Analysis of The Cancer Genome Atlas (TCGA) and UALCAN datasets revealed marked upregulation of SHP2 and multiple receptor tyrosine kinases in gastric cancer tissues. NSC 57774 potently inhibited cell proliferation and migration, demonstrating selective cytotoxicity towards cancer cells over non-cancerous fibroblasts. Mechanistically, NSC 57774 disrupted key oncogenic pathways including MAPK/ERK, AKT and STAT3 in a concentration-and timedependent manner, with higher doses achieving more sustained pathway suppression. NSC 57774 suppressed NF-κB inflammatory signaling at early timepoints and induced cleaved caspase-3 across all treatment groups at 72 hours, indicative of pro-apoptotic activity. A paradoxical late-phase increase in phospho-p38 was observed at 72 hours, consistent with a compensatory pro-apoptotic stress response. Comparative analysis revealed that NSC 57774 outperformed the commercial SHP2 inhibitor NSC 87877 and doxorubicin in reducing viability and migration of gastric cancer cells. Collectively, these findings position NSC 57774 as a promising candidate for target","cbCaislfmoOUfZXw","https://ap.wps.com/l/cbCaislfmoOUfZXw","pdf",2330829,22,"English","# Abstract\n# Introduction\n# Mechanistic evaluation","[{\"question\":\"What is NSC 57774 and what does this study evaluate?\",\"answer\":\"NSC 57774 is a novel SHP2 inhibitor. The study evaluates its anti-cancer efficacy and mechanistic impact on signaling pathways in gastric cancer cells in vitro.\"},{\"question\":\"How did the authors investigate SHP2 involvement in gastric cancer?\",\"answer\":\"They used integrated bioinformatics, analyzing TCGA and UALCAN datasets to identify upregulation of SHP2 and multiple receptor tyrosine kinases in gastric cancer tissues.\"},{\"question\":\"Which signaling pathways are reported to be disrupted by NSC 57774?\",\"answer\":\"NSC 57774 disrupted key oncogenic pathways including MAPK/ERK, AKT, and STAT3, and it suppressed NF-κB inflammatory signaling at early timepoints.\"}]","Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer - Multi-pathway signaling modulation in vitro | PDF",1790059309,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00cb1214d5b013ab0b5000b2dce13f91.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fed1035cb9937cafb4409289ca2e0a3.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb7e19b4d9f902fa08b16cc22fa71684.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ac448d52a2fbb469aaaa9b4f7ca866b.webp",980,1268]